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Abstract
Background: Intracerebral inoculation of extracts from post-mortem human Alzheimer’s disease brains into mice
produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the
synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cytosolic protein
aggregates, suggest that brain extracts contain key contributors that enhance the prion-like effect of amyloid-β.
Nevertheless, these potential partners are still unknown due to the complexity of whole brain extracts.
Methods: Herein, we established a method based on sequential detergent solubilization of post-mortem samples
of human brains affected by Alzheimer’s disease that strongly enrich amyloid-β aggregates by eliminating 92% of
the remaining proteins. Internalization of Aβ1–42 from the enriched AD extracts was evaluated in vitro, and
internalization of fluorescent-labeled AD extracts was also investigated in vivo. Furthermore, we carried out a
molecular characterization of the Aβ-enriched fraction using label-free proteomics, studying the distribution of
representative components in the amygdala and the olfactory cortex of additional human AD brain samples by
immunohistochemistry.
Results: Aβ1–42 from the enriched AD extracts are internalized into endothelial cells in vitro after 48 h. Furthermore,
accumulation of fluorescent-labeled Aβ-enriched extracts into mouse microglia was observed in vivo after 4 months
of intracerebral inoculation. Label-free proteomics (FDR < 0.01) characterization of the amyloid-β-enriched fraction
from different post-mortem samples allowed for the identification of more than 130 proteins, several of which were
significantly overrepresented (i.e., ANXA5 and HIST1H2BK; p < 0.05) and underrepresented (i.e., COL6A or FN1; p <
0.05) in the samples with Alzheimer’s disease. We were also able to identify proteins exclusively observed in
Alzheimer’s disease (i.e., RNF213) or only detected in samples not affected by the disease (i.e., CNTN1) after the
enrichment process. Immunohistochemistry against these proteins in additional tissues revealed their particular
distribution in the amygdala and the olfactory cortex in relation to the amyloid-β plaque.
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Conclusions: Identification and characterization of the unique features of these extracts, in terms of amyloid-β
enrichment, identification of the components, in vitro and in vivo cell internalization, and tissue distribution,
constitute the best initial tool to further investigate the seeding and transmissibility proposed in the prion-like
hypothesis of Alzheimer’s disease.
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Background
Alzheimer’s disease (AD) is the main cause of dementia
worldwide [1, 2]. From a neuropathological point of
view, Alzheimer’s disease (AD) is characterized by the
deposition of insoluble forms of amyloid-β (Aβ) in the
brain parenchyma and abnormal hyperphosphorylation
of tau protein, forming, respectively, plaques and neuro-
fibrillary tangles [3]. Even though these pathological fea-
tures are well-known, the etiology of the disease is still
unknown. Together with the accepted amyloid hypoth-
esis [4, 5], the prion-like hypothesis is gaining strength
to explain the etiology of neurodegenerative diseases
characterized by proteinopathies—such as AD [6], whose
initial stages reportedly begin in the mesial temporal
structures [7]. This hypothesis is based on the capacity
of Aβ to induce abnormal folding of native adjacent pro-
teins and cell-to-cell propagation of Aβ and tau, resem-
bling a prion-like seeding and spreading mechanism [8].
This idea is supported by the fact that inoculation of hu-
man brain extracts obtained either from patients with
AD [9–11] or from APP23 mice [12] into transgenic
mice [9–12] or marmosets (Callithrix jacchus) [13] in-
duces the development of diffuse plaques far from the
injection site [9, 10].
Prion-like spreading of AD appears to follow a three-
step process. First, after injection of AD extracts, the
seeds (mostly oligomers and protofibrils) are internalized
by using a variety of mechanisms [14]. Second, internal-
ized seeds nucleate the fibrillation of native monomers
in the cytoplasm of the recipient cell, and a positive
feedback loop starts [15]. Finally, cell-to-cell transmis-
sion of cytosolic protein aggregates starts after their re-
lease into the extracellular space in their “naked” form
[15]. Different proteomic analyses have been performed
using Aβ-enriched extracts [16–22] and micro-dissected
plaques coupled with LC-MS/MS [23–26], in order to
identify additional components which may be relevant
to both transmissibility and seeding process. Usually, AD
brain extracts are inoculated directly into the brain of
APP23 [10, 11] or tg2576 transgenic mice [9] to evaluate
the prion-like hypothesis. To our knowledge, none of
the published studies has assessed the possibility of in-
jection of fractions enriched with Aβ plaques. This study
proposes a method that strongly enriches Aβ aggregates
from human AD samples while retaining their ability to
internalize Aβ in vitro and in vivo. Proteomic
characterization of these extracts revealed the presence
of several proteins either over- or underrepresented in
AD-enriched fractions, which may contribute to plaque
integrity and/or Aβ internalization.
Materials and methods
Human brain samples
Human tissue blocks were provided by biobanks IDI-
BAPS (Barcelona), BT-CIEN (Madrid), and BIOBANC-
MUR (Murcia). Experimental procedures were approved
by the Ethical Committee for Clinical Research of the
Ciudad Real University Hospital. Twelve human brain
samples containing the olfactory cortex, amygdala, and
hippocampus were used (five diagnosed AD cases, six
cases with no AD diagnosis, and one case with inciden-
tal plaques but no AD diagnosis; Additional file 1: Table
S1). The exact locations of the brain sections used in this
study are shown in Additional file 2: Figure S1.
Enrichment of Aβ plaque-containing fractions from
human brains
To obtain Aβ-enriched fractions, we used two samples
from human brains with no AD diagnosis, two cases di-
agnosed as AD (stage VI), and one case with incidental
Aβ plaques but no AD diagnosis (Additional file 1: Table
S1). Approximately 10 g from each sample was cut into
1-cm3 blocks and homogenized in lysis buffer (20 mM
Tris pH 7.4, 100 mM NaCl and 5mM CaCl2) supple-
mented with protease inhibitor. Homogenization was
performed on a mechanical homogenizer on ice. The
homogenates were incubated on ice with DNase I. An
efficient enrichment of Aβ plaques from the human
brain was achieved using a protocol based on four cen-
trifugation steps using Triton X (1%) and SDS (1.75%)
followed by acetone precipitation (Additional file 2: Fig-
ure S2A). This protocol was applied to two human brain
samples with no evidence of AD pathology (non-AD;
n = 2), samples from two AD patients (AD; n = 2), and
also one sample from a patient with diffuse plaques but
no evidence of AD (DP; n = 1), for comparison. An over-
view of the process is shown in Additional file 2: Figure
S2A. The resulting precipitate was resuspended in
Hank’s solution and stored at − 20 °C.
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Determination of the efficacy of Aβ enrichment
The Aβ1–42 content (the major component of Aβ pla-
ques in the brain parenchyma) of the fractions was ex-
amined with dot blot (Additional file 2: Figure S2B-C)
and western blot (Fig. 1A). Dot blot was carried out with
1 μl of each fraction resulting from the enrichment pro-
cedure, which was set on PVDF membranes. PVDF
membranes were dried during 2 h at 60 °C and blocked
with 5% BSA (VWR, Solon; OH, USA) in TTBS (200
mM Tris-HCl pH 8.8, 6 mM NaCl and 1% Tween20) for
1 h at room temperature. Membranes were blotted with
Aβ1–42 (1:5000) and tau (1:1000) antibodies. For western
blot, all the protein extracts were quantified using
bicinchoninic acid assay (BCA; Sigma Aldrich). Sixty
Fig. 1 Quantification and evaluation of the Aβ-enriched extracts. a Western blot of AD sample 1 (AD1) and diffuse plaque sample (DP) using
Aβ1–42 antibody. The last fraction enriched in Aβ plaques is shown boxed in order to identify Aβ monomer (4-kDa band), dimers, and multimers.
b Ratio between western blot signal and Coomassie blue staining that reflects Aβ enrichment in the fractions. c ELISA of Aβ1–42 carried out with
non-AD (non-AD1 and non-AD2), AD (AD1 and AD2), and DP samples. c Dot blot on the enriched extracts (P4) of the samples previously
analyzed with western blot and ELISA. SEM images of AD1 extracts (a, b), AD2 extracts (c, d), DP extracts (e, f), and non-AD extracts (g, h). Scale
bars: a, c, e, g, 1 μm and b, d, f, h, 200 nm
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micrograms of protein for each sample (all supernatants
and pellet) was prepared using 12.5-μL sample buffer
(Bio-Rad), 2.5-μL reducing buffer (Bio-Rad), and deion-
ized water, and boiled for 5 min. Samples were electro-
phoresed on Criterion™ XT Precast Gel 12% Bis-Tris
(Bio-Rad) with XT MES running buffer (Bio-Rad) at 180
V for 45 min. The proteins were transferred to a PVDF
membrane (Bio-Rad) for 50 min at 0.25 mA constant in
transfer buffer (50 mM Tris-HCL, pH 8.8, 192 mM gly-
cine, 0.02% SDS and 20% methanol). Membranes were
stained with ponceau red and destained with 1% acetic
acid and blocked in 5% BSA in TTBS for 1 h at room
temperature and then incubated with Aβ1–42 antibody
(1:1000; 2.5% BSA in TTBS) overnight at 4 °C. After sec-
ondary antibody incubation, the membranes were
washed with TTBS and developed with Clarity Western
ECL substrate according to the manufacturer’s direc-
tions. To evaluate the effectiveness of the enrichment
Aβ1–42, western blot results were compared with Coo-
massie blue staining of 20 μg of all the fractions by
quantifying the ratio with ImageJ.
Quantification of Aβ1–42 contents in the enriched fraction
Quantification of the Aβ contents in the final enriched
fraction was done by dot blot and ELISA after sonicating
the samples. ELISA was performed using an Aβ42 Hu-
man ELISA Kit (Invitrogen; Vienna, Austria) following
the manufacturer’s instructions. The samples were soni-
cated (Branson Ultrasonics™ Sonifier™ SFX150) for 1
min. Dot blot was performed as described previously
using different dilutions of the extract and dilutions of
the synthetic Aβ1–42 peptide with known concentrations.
Scanning electron microscopy (SEM)
The presence of aggregates in the Aβ-enriched extracts
was confirmed by SEM after sonication. The homoge-
nates were diluted in methanol and centrifuged at
16100g for 10 min at 4 °C, twice. The resulting pellets
were resuspended in pure methanol, then deposited in
silicon and left to dry. Samples were metallized with gold
chips and observed using a Zeiss GeminiSEM 500 scan-
ning electron microscope.
In vitro Aβ1–42 internalization into endothelial cells
Internalization of Aβ1–42 from enriched extracts was ex-
amined in vitro. As endothelial cells are the first to inter-
act with the circulating Aβ, we used for these studies the
endothelial cell line bEnd.3 (ATCC CRL-2299). Cells
were cultured in DMEM containing 10% fetal bovine
serum (FBS) and 1% antibiotic/antimycotic, at 37 °C and
5% CO2. They were then seeded in eight-well μ-Slides
(Ibidi, Martinsried, Germany) and incubated with AD
and non-AD extracts. After 48 h, cells were fixed and
permeabilized in 4% paraformaldehyde (PFA). To
analyze Aβ incorporation, cells were sequentially incu-
bated with Aβ1–42 antibody (1 h) and AlexaFluor® 488-
conjugated anti-mouse antibody (1 h). Cells were co-
stained with 1 μg/ml Hoechst and ActinRed™ 555 and
examined using an LSM 800 confocal microscope (Zeiss;
Jena, Germany) with a × 63 objective.
In vivo microinjection of Aβ-enriched fractions
In vivo experiments were carried out with female
C57BL/6J mice (000654, The Jackson Laboratory, USA).
Three different experimental groups were established:
saline microinjection (n = 6), human non-AD extract
microinjection (n = 6), and human AD Aβ-enriched ex-
tract microinjection (n = 6). Animals were anesthetized
using vaporized isoflurane. The animals were placed in a
Kopf (Tujunga, CA) stereotaxic apparatus, and the skull
trepanned at the injection spot into the dorsal part of
the left anterior olfactory nucleus (AONd, coordinates
from Bregma [27] were AP = + 2.8 mm, L = 1mm, and
depth = − 2.75 mm, from the dura mater). This structure
was chosen because it is preferentially vulnerable and
directly involved in Aβ aggregation [28, 29]. Next, saline,
6 μg/μl of human non-AD and 6 μg/μl of human Aβ1–42-
enriched extracts (all extracts were previously tagged
with AlexaFluor® 488 nm [green] labeling dye [Molecular
Probes]) were injected in a constant infusion (0.2 μl/
min) for 10 min using a microsyringe (10 μL Neuros
Model 1701 RN, point style 4, SYR, Hamilton Co., Nev-
ada, USA). Animals were kept on the stereotaxic appar-
atus for additional 5 min to favor the diffusion of the
extract before removing the syringe. The animals were
housed on a standard 12/12 h light/dark cycle, at 21 °C
with food and water ad libitum. All the animal research
procedures described herein were in agreement with
European (Directive 2010/63/EU) and Spanish (RD 53/
2013) legislation on the protection of animals used for
scientific purposes. All experiments described were ap-
proved by the Ethical Committee for Animal Research
of the University of Castilla-La Mancha (SAF2016-
75768-R).
Isolation of mouse brain for immunostaining
Four months after injection, animals were anesthetized
with a mixture of ketamine hydrochloride (1.5 mL/kg,
75 mg/kg, Ketolar, Madrid, Spain) and xylazine (0.5 mL/
kg, 10 mg/kg, Xilagesic, Calier, Barcelona, Spain) and
perfused with saline solution followed by 4% w/v para-
formaldehyde fixative (phosphate-buffered; 0.1 M so-
dium phosphate, pH 7.2). Brains were post-fixed in 4%
w/v paraformaldehyde, cryo-protected in 30% w/v su-
crose, and coronally sectioned (50 μm) employing a
freeze sliding microtome. To visualize the injection site,
sections were counterstained with DAPI. To study the
extracts injected into the AONd, saline, human non-AD
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extracts, and human Aβ1–42-enriched extracts were
tagged with AlexaFluor® 488 nm (green) dye, following
the manufacturer’s instructions. Immunofluorescence la-
beling against Iba-1 (1:1000) and AlexaFluor® 568 nm (1:
200) was performed in order to detect microglia.
Label-free proteomics of human brain extracts
For proteomics analysis, two AD samples, two non-AD
samples, and one corresponding to a patient with pre-
amyloid diffuse plaques but without evidence of AD
were used (all samples were enriched as described in the
previous section). The protein extracts (150 μg per sam-
ple) were concentrated on gel and analyzed by reverse
phase liquid chromatography-tandem mass spectrometry
(RP-LC-MS/MS) using an Easy-nLC II system coupled
to a linear ion trap mass spectrometer model LTQ
(Thermo Scientific) as previously described [30]. The
MS/MS raw files were searched against the Uniprot–Hu-
man proteome database (70,931 entries in January 2019)
(http://www.uniprot.org) using the SEQUEST algorithm
(Proteome Discoverer 1.4, Thermo Scientific). The fol-
lowing constraints were used for the searches: tryptic
cleavage after Arg and Lys, up to two missed cleavage
sites, and tolerances of 1 Da for precursor ions and 0.8
Da for MS/MS fragment ions and the searches were per-
formed allowing optional Met oxidation and Cys carba-
midomethylation. A false discovery rate (FDR < 0.01)
and at least two peptides per protein was considered as
a condition for successful peptide assignments. For the
semiquantitative analysis of proteins, the total number
of peptide-spectrum matches (PSMs) for each protein
was normalized against the total number of PSMs in
each sample and compared between AD and non-AD
samples using the chi-square test (p < 0.05).
Gene ontology analysis study was carried out with the
proteomic profiles obtained for both AD and non-AD-
enriched extracts to identify overrepresentation profiles.
To that end, we use GOrilla (http://cbl-gorilla.cs.tech-
nion.ac.il; [31]), a bioinformatics tool previously used in
several studies (i.e., [32]). As a background, we used the
most recent database of a global quantitative analysis of
the human brain proteome in Alzheimer’s disease, ex-
tracted from [33] (16,559 recognized proteins in GOrilla;
database updated June 2019). We set p value to 10− 6 in
order to avoid unreliable data. Gene ontology was inves-
tigated at three levels: biological process, biological func-
tion, and biological component.
Immunofluorescence and immunohistochemical
procedures
Immunofluorescence analysis was performed in 4%
phosphate-buffered formaldehyde-fixed samples. After-
wards, all blocks were post-fixed in fresh 4% phosphate-
buffered paraformaldehyde for 45 days. Coronal sections
of the amygdala, olfactory cortex, and hippocampus
(50 μm) were obtained using a freezing sliding micro-
tome Microm HM 450. For these experiments, a total of
six antibodies against Aβ1–42, RNF213, COL6A, ANXA5,
CNTN1, and GFAP were used (Additional file 1: Table
S2). Tissue antigenicity was unmasked by boiling the tis-
sue under pressure for 2 min in citrate buffer. Sections
were immersed in formic acid for 3 min and rinsed in
phosphate buffer. Endogenous peroxidase activity was
inhibited by a 30-min bath in 1% H2O2 in phosphate-
buffered saline. Blocking consisted of 5% NDS+ 0.3%
Triton X-100 in PBS. Sections were incubated overnight
at 4 °C with primary antibodies containing 0.3% Triton
X-100 and 5% normal serum in phosphate-buffered sa-
line. Controls included omitting primary or secondary
antibodies. Sections were counterstained using DAPI
(Santa Cruz Biotechnology; Inc.; Sc-3598) or Nissl and
coverslipped with PVA-DABCO or DPX after dehydrat-
ing. Human tissue autofluorescence was not reduced.
Images were captured using an LSM 800 confocal
microscope and analyzed using ZEN software.
Results
Detergent-centrifugation method allows efficient
enrichment of insoluble Aβ1–42
The presence of Aβ1–42 in the five samples during the
different steps was monitored by dot blot [Add-
itional file 2: Figure S2B (non-AD1, AD1 and DP) and
Additional file 2: Figure S2C (non-AD2 and AD2)]. As
expected, the results showed no Aβ1–42 in the non-AD
samples. The SDS 1.75% supernatants (S3–S4) showed
immunostaining both in AD and DP samples, suggesting
that part of the soluble Aβ1–42 was diluted using this
concentration of SDS. In AD samples, the pellet from
the last step was extremely difficult to reconstitute and
showed a strong Aβ1–42 signal (probably corresponding
to the Aβ plaques). Interestingly, the DP samples did not
show reactivity in the insoluble fraction (Additional file 2:
Figure S2B), and tau protein was mainly eliminated in
the second wash with SDS (Additional file 2: Figure
S2D). A 4-kDa band was observed with strong immuno-
reactivity against Aβ1–42 in the last fraction of the AD
and DP samples (Fig. 1A), probably corresponding to
monomeric Aβ1–42. Aβ1–42 dimers, trimers, and oligo-
mers appeared only in the AD samples (Fig. 1A, right),
indicating that AD and DP experience different aggrega-
tion strengths.
Estimation of Aβ1–42 enrichment (Fig. 1B) was
attempted by comparing western blot and Coomassie
blue staining (Additional file 2: Figure S2E). In AD sam-
ples, the concentration of Aβ1–42 increased according to
the ratio western blot/Coomassie blue staining (Fig. 1B,
left). In the DP sample, the ratio did not change (Fig. 1B,
right). In order to accurately quantify Aβ1–42
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concentration, a human Aβ1–42 ELISA (Invitrogen;
Fig. 1C) was performed. Despite the sensitivity of the kit,
non-AD samples did not show immunoreactivity against
Aβ1–42. It is especially relevant that although AD sam-
ples contained 50 ng/mL (AD1) and 210 ng/mL (AD2) of
Aβ1–42, the DP sample showed a higher concentration of
Aβ1–42 (over 0.8 μg/ml). This result is completely oppos-
ite to that obtained with western blot and dot blot. To
quantify Aβ concentration in the extracts, dot blot with
diluted concentrations of the Aβ-enriched fractions and
known dilutions of synthetic Aβ1–42 [34] (Sigma Aldrich;
Fig. 1D) was carried out. The results indicated a concen-
tration of Aβ1–42 in the sample ranging from 0.1 to
0.5 μg/μL. Although we are aware that neither of the
methods developed so far for insoluble Aβ1–42 quantifi-
cation are accurate, the examination of our samples by
electron microscopy revealed the presence of aggregates
(with the presence of fibrils) in AD (Fig. 1E, a–d) and
DP (Fig. 1E, e–f ) sonicated extracts, which were not ob-
served in non-AD samples (Fig. 1E, g–h).
Aβ internalization from the enriched fractions into
cultured microvascular endothelial cells
Our Aβ plaque enrichment protocol was aimed at main-
taining the plaque integrity and to preserve its prion-like
properties. Therefore, we first evaluated the in vitro in-
corporation Aβ1–42 internalization into bEnd.3 cells were
tested by adding AD-enriched extracts (a volume corre-
sponding to approximately 1 μg of Aβ1–42 according to
dot blot quantification) to the cell culture. Figure 2
shows immunofluorescence against the Aβ1–42 antibody
and ActinRed™ 555 labeling after 48-h incubation with
non-AD extracts (Fig. 2a) and Aβ-enriched extracts from
AD1 (Fig. 2b, c) and AD2 (Fig. 2d, e). This strategy
allowed us to visualize internalized Aβ1–42 in vesicle-like
structures using confocal z-stacks (Fig. 2b–e). Add-
itional file 3: Video S1. shows different angles of the
Aβ1–42 internalized in the cell from Fig. 2b.
In vivo injection of Aβ plaque-enriched extracts in mouse
brain and Aβ1–42 internalization
Aβ-enriched extracts tagged with AlexaFluor® 488 nm
(green) were injected into the dorsal part of the anterior
olfactory nucleus. Labeled saline injections (images not
shown) did not reveal any fluorescence near the injec-
tion site. Inoculation with the extracts obtained non-AD
sample allowed for the identification of the injection site,
but no fluorescence was detected inside the cells (Fig. 3a,
b). In contrast, the fluorescence of the sections 4 months
after inoculation of Aβ1–42-containing extracts could be
observed inside the cells closer to the injection location
(Fig. 3c, d). Internalization of human Aβ extracts (green)
in microglia was also examined using Iba-1 antibody
(red; Fig. 3e). Figure 3f shows an Iba-1-positive cell
within the z-stack.
Proteomic characterization of Aβ-enriched extracts
Next, the enriched fraction containing insoluble Aβ was
characterized in order to identify possible protein com-
ponents bound to the Aβ plaque that had not been ob-
served in the non-AD extracts. To that end, proteomic
analysis on enriched extracts of two AD and two non-
AD samples was performed. Specifically, 149 and 133
proteins were identified in AD-enriched samples, and
144 and 131 in non-AD samples (Additional file 4: Table
S3.) In AD samples, six of these proteins were overrepre-
sented and three proteins were underrepresented
(Table 1). Proteins that were exclusively detected in AD
or non-AD extracts were also examined (Table 2; 1%
FDR, target-decoy database approach). A total of 34 pro-
teins were identified at least in one of the two AD sam-
ples, while 12 proteins were identified in the non-AD
extracts, which probably correspond to proteins that de-
crease in AD-enriched extracts. Several proteins previ-
ously related to AD were identified as overrepresented
in the Aβ-enriched fraction [APOE [35], ANXA2 [36],
or MAPT [37]]. The rest of the identified proteins are
shown in Table 2.
GO enrichment analysis was carried out with the pro-
teins observed in the enriched samples of both AD and
non-AD, using whole brain proteome as background.
This study retrieved significant results when biological
process was inquired (Additional file 2: Figure S3). Thus,
negative regulation of wound healing and homeostasis
were identified an AD while cell morphogenesis and cell
junction assembly appeared in the non-AD samples.
Distribution of the proteins in the amygdala and olfactory
cortex sections
GFAP, ANXA5, and COL6A expression was evaluated
by immunofluorescence. Since proteomics had been per-
formed in regions containing mostly amygdala (see Add-
itional file 2: Figure S1), immunohistochemical
experiments were performed in the same regions using
additional AD samples. Furthermore, several of the pro-
teins in the olfactory cortex area were also examined in
order to evaluate whether the changes induced in AD
could also be observed in this section of the brain—since
olfactory deficits usually precede the clinical onset of
cognitive and memory deficits in AD pathology [38].
GFAP expression was examined as a control of the en-
richment process, since it has been previously shown to
co-localize with the Aβ plaque in AD [39]. The results
indicated that although there was co-localization be-
tween Aβ1–42 and GFAP, GFAP immunolabeling in AD
could be observed in all the tissue (Fig. 4A). ANXA5
was also overrepresented in Aβ1–42 extracts.
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Immunostaining was higher in AD samples than in non-
AD samples in both the amygdala (Fig. 4B) and the ol-
factory cortex (Additional file 2: Figure S4A). However,
in contrast with GFAP, the ANXA5 signal increase was
especially noticeable surrounding the plaques in human
AD brain samples. As for COL6A, which was highly rep-
resented in non-AD samples, it also showed reduced im-
munostaining in AD samples (Fig. 4C).
Finally, a triple immunofluorescence was carried out in
amygdala with Aβ1–42 (Fig. 5a, b, red) and two of the pro-
teins observed exclusively in AD samples (RNF213; Fig. 5c,
d, green) and non-AD samples (CNTN1; Fig. 5e, f, purple)
. It is especially relevant that CNTN1 expression in non-
AD samples was strong and widespread when compared
to AD samples (Fig. 5e, f ). On the other hand, RNF213
immunostaining (which, as expected, appears in the nuclei
of the cells) seems to be overexpressed in AD samples.
Together with the Aβ1–42 fluorescence (Fig. 5g, h), a note-
worthy increase in RNF213 intensity (twofold increase)
could be appreciated when the nuclei were located into
Aβ plaques (arrow). Similar experiments performed in the
olfactory cortex of AD patients revealed that CNTN1 was
also highly abundant in non-AD samples in this section of
the brain (Additional file 2: Figure S4B) while RNF213 ap-
peared strongly associated within the limits of the Aβ
plaque (Additional file 2: Figure S4B).
Discussion
Aβ enrichment from AD patients and pre-amyloid diffuse
plaques
Several laboratories have developed protocols to extract
Aβ and other components from AD plaques [17, 19, 22,
Fig. 2 Immunofluorescence against Aβ1–42 in ActinRed™ 555-labeled endothelial cells (bEnd.3) after 48-h incubation with the enriched extracts. a Non-AD
extracts. b, c Two representative cells after incubation with AD1-enriched extracts. d, e Two representative cells after incubation with AD2-enriched extracts. Z-
stacks are shown on the top and right sides of each image. Pictures were acquired using a confocal microscope with a × 63 objective. Scale bars a–d=10μm
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40] although those with higher success rates (70–99%
formic acid; [22]) involve aggressive treatments of the
Aβ plaque and solubilize the core structure of amyloid
fibrils [22]. In this study, we aimed at preserving as
much fibrillar structures as possible and therefore we
used a four-step enrichment protocol based on detergent
centrifugations. We avoided the combination of deter-
gent extraction with high molarity urea or guanidinium
Fig. 3 Microinjection and internalization of Aβ1–42 in the dorsal anterior olfactory nucleus. Images show the region where the AlexaFluor 488-
labeled extracts were injected. Human non-AD extracts (a, b) and human Aβ1–42-enriched extracts (c, d). Nuclei are shown in blue (DAPI), and
labeled extracts appear in green. Images e and f correspond to the tissue of samples injected with labeled extracts (green) together with Iba-1
labeling (red). Z-stack images are also shown. Scale bars a, c = 130 μm, b = 20 μm, d = 40 μm, e = 10 μm, f = 3 μm. AO anterior olfatory nucleus (D,
dorsal; L, lateral; M, medial; V, ventral)
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salts as it may result in increased solubilization of fibril-
lar structures [41]. We also avoided sonication during
the process as it has been shown that it produces the re-
distribution of Aβ species from plaques to more soluble
fractions [41].
In AD, Aβ aggregates start as pre-amyloid diffuse pla-
ques [42] that contain smaller amounts of Aβ and are
not as organized into fibrils as in more advanced stages.
In this study, a strong precipitate was observed in Aβ-
enriched samples of stage VI AD patients, and dimers
and oligomers remained in western blot experiments.
The presence of such insoluble material was not ob-
served in non-AD samples and barely observed in the
extract from the patient with diffuse plaques. Neverthe-
less, in order to obtain accurate information of the sol-
uble Aβ that was present in each enriched extract used
for the different experiments, we avoided the use of for-
mic acid or guanidinium salts for ELISA. Quantification
in such conditions uncovered the presence of five to ten
times higher Aβ1–42 in DP than in AD. In this sense, it
has been shown that ELISA usually works fine with sol-
uble Aβ but not with insoluble Aβ aggregates as it un-
derestimates the concentration of total Aβ1–42 of the Aβ
plaque [43]. Taking into consideration the solubility of
Aβ in the AD samples, it was not possible to ascertain
their Aβ1–42 concentration, and only dot blot analysis
(which has previously been used for this purpose) [34]
gave an approximated concentration of 0.5 μg/μl of Aβ
in the final pellet. Although we are aware that the pres-
ence of insoluble material may introduce some bias in
the process of protein quantification, as far as we know,
this concentration constitutes the highest Aβ enrich-
ment tested to date in vivo and in vitro.
Labeled extracts from Aβ-enriched fractions are
internalized in vitro and in vivo
This study provides the first evidence that AD-enriched
extracts, but not non-AD extracts, are efficiently incor-
porated into the cells surrounding the injection site 4
months post-injection, which constitutes the first step
toward Aβ transmissibility. Additional labeling with Iba-
1 demonstrates that among the cells that incorporate la-
beled extracts of AD patients in vivo there are glial cells
(microglia). This fact has been previously described in
vitro [34], where it was proposed that Aβ1–42 protofibrils
were more efficiently internalized by microglia than
monomers [34]. In fact, microglia might play a crucial
role in AD [44]. We cannot assure that the long-lived
component of the extracts incorporated into Iba-1-
positive cells is exclusively Aβ1–42 as we labeled whole
Aβ1–42-enriched extracts. In fact, there exists the possi-
bility that the observed fluorescence corresponds to add-
itional labeled proteins that are not enriched in control
extracts, as these extracts are not internalized. In this
sense, previous experiments injecting preparations of
soluble or fibrillar synthetic Aβ40, Aβ42, or a mixture of
both [11] and Aβ1–40, Aβ1–42, and Aβ40–1 synthetic Aβ
peptides [13] did not generate such a prion-like effect as
AD brain extracts, suggesting that these extracts may
contain unique features important for the internalization
and transmission of the seeding. Also, further attempts
to initiate the aggregation of Aβ in vivo with synthetic
peptides in combination with several of the components
known to be associated with the Aβ plaque, such as
ApoE [11], did not reach success reinforcing the idea
that other plaque components should be participating in
this phenomenon. This is especially relevant, and we are
Table 1 Proteins overrepresented in Aβ-enriched fraction and proteins overrepresented in non-AD samples. The MS/MS raw files
were examined against the universal protein database UniProt (70,931 entries in January 2019) (http://www.uniprot.org), using the
SEQUEST algorithm (Proteome Discoverer 1.4, Thermo Fisher Scientific). Fold of change; P value < 0.05. PSM peptide-spectrum
matches, x̄ average, ND-AD not detected in Alzheimer extracts, ND-non-AD not detected in control extracts
















A) Proteins overrepresented in AD enriched fractions
GFAP Glial fibrillary acidic protein P14136 36 48 71 100 42 85.5 2.04 1E−4
MBP Myelin basic protein J3QL64 11 14 41 17 12.5 29 2.32 0.013
SH2D3C SH2 domain-containing protein 3C
(fragment)
Q5JU32 19 2 47 2 10.5 24.5 2.33 0.019
ANXA5 Annexin A5 P08758 0 0 4 15 0 9.5 ND–non AD 0.001
HIST1H2BK Histone H2B type 1-K O60814 0 0 9 1 0 5 ND–non AD 0.025
ANXA2 Annexin A2 H0YMM1 0 0 2 6 0 4 ND–non AD 0.045
B) Proteins overrepresented in non-AD enriched fractions
COL6A3 Collagen alpha-3(VI) chain E7ENL6 13 28 0 7 20.5 3.5 5.86 6E−4
FGB Fibrinogen beta chain P02675 15 23 0 15 19 7.5 2.53 0.034
FN1 Fibronectin P02751 2 5 0 0 3.5 0 ND–AD 0.045
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Table 2 Proteins found exclusively in AD extracts and proteins found exclusively in non-AD extracts
Symbol Entrez gene name ID PSM
A) Proteins found exclusively in AD extracts
ANXA5 Annexin A5 P08758 19
HIST1H2BK Histone cluster 1 H2B family member k O60814 10
ANXA2 Annexin A2 H0YMM1 8
DNAH11 Dynein axonemal heavy chain 11 Q96DT5 5
HIST1H2BA Histone cluster 1 H2B family member a Q96A08 5
XRCC5 X-ray repair cross complementing 5 P13010 5
APOE Apolipoprotein E P02649 4
CFAP43 Cilia and flagella associated protein 43 Q8NDM7 4
RNF213 Ring finger protein 213 A0A0A0MTR7 4
RPL4 Ribosomal protein L4 H3BM89 4
HBB Hemoglobin subunit beta F8W6P5 3
MAPT Microtubule associated protein tau I3L170 3
NME1-NME2 NME1-NME2 readthrough J3KPD9 3
PIK3R2 Phosphoinositide-3-kinase regulatory subunit 2 E9PFP1 3
SEPT2 Septin 2 B5MCX3 3
SYNE2 Spectrin repeat containing nuclear envelope protein 2 G3V5X4 3
CCDC171 Coiled-coil domain-containing 171 H0Y5M5 2
CD9 CD9 molecule A6NNI4 2
CFAP47 Cilia and flagella associated protein 47 A0A140T8X2 2
DHH Desert hedgehog O43323 2
EFHB Ef-hand domain family member B Q8N7U6 2
ESRP1 Epithelial splicing regulatory protein 1 Q6NXG1 2
IQSEC2 IQ motif and sec7 domain 2 Q5JU85 2
LRP1B LDL receptor-related protein 1B Q9NZR2 2
MAG Myelin-associated glycoprotein M0QZU4 2
MARCH1 Membrane-associated ring-ch-type finger 1 D6RGC4 2
MYBPC3 Myosin binding protein C, cardiac A0A0A0MQU5 2
NME1 NME/NM23 nucleoside diphosphate kinase 1 P15531 2
ODF2 Outer dense fiber of sperm tails 2 Q5BJF6 2
PLPPR4 Phospholipid phosphatase related 4 Q7Z2D5 2
PLXNC1 Plexin C1 O60486 2
SCUBE1 Signal peptide, CUB domain and EGF like domain-containing 1 A0A087X285 2
SLC12A6 Solute carrier family 12 member 6 B3KXX3 2
TGFBI Transforming growth factor beta induced H0Y8L3 2
B) Proteins found exclusively in non-AD extracts
FN1 Fibronectin 1 P02751 7
LAMA5 Laminin subunit alpha 5 O15230 5
ATP5F1B ATP synthase F1 subunit beta P06576 4
DNAH12 Dynein axonemal heavy chain 12 Q6ZR08 3
ACTN1 Actinin alpha 1 H0YJ11 2
ARHGEF26 Rho guanine nucleotide exchange factor 26 Q96DR7 2
CEP152 Centrosomal protein 152 O94986 2
CFL1 Cofilin 1 E9PLJ3 2
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currently undergoing further experiments to identify the
nature of the incorporated proteins. In addition, our
study also found that cultured endothelial cells, as the
primary components of the blood–brain barrier, uptake
Aβ extracts from Aβ-enriched fractions in what may
constitute the pathway for Aβ to reach the bloodstream.
Proteomics analysis identified components that were
over- and underrepresented in plaque-containing AD
extracts
Previous studies [39, 45] have related a hyper-reactivity
of the GFAP protein to Aβ deposition. In this study, the
GFAP signal was found to be intense in the amygdala of
AD patients, corroborating those findings. Two mem-
bers of the annexin family were also enriched in AD ex-
tracts. One of them, annexin A5 (ANXA5), has been
proposed as an AD biomarker since its plasma levels,
commonly used to detect apoptotic cells, are signifi-
cantly higher in AD patients [46, 47]. Intense ANXA5
immunoreactive spots were observed in an AD trans-
genic mouse model [47]. Our study shows for the first
time that the ANXA5 signal is especially intense several
micrometers around the plaque. In this sense, GO en-
richment analysis revealed overrepresentation of two
biological processes in AD extracts, where ANXA5, to-
gether with ANXA2, APOE, and CD9 proteins take part:
negative regulation of wound healing and homeostasis.
These biological processes are not found in non-AD ex-
tracts and enhance the potential importance of these
four proteins for systemic inflammation, or other pro-
cesses that lead to the brain homeostasis collapse in ad-
vanced Alzheimer’s disease stages [48].
It is especially intriguing that the presence of
HIST1H2BK among the most significant proteins is
overrepresented in Aβ-enriched extracts. This fact has
been observed for histone H3 previously in full extracts
off AD by iTRAQ [49] and in laser proteomics of the
plaques for histone H4 [25]. Search for ligands of b-APP
using ligand blotting showed strong affinity for histones
specially H4 [50], and although we do not know whether
histones bind or not to APP-derived peptides, their con-
sistent finding in proteomic studies points toward a deep
histone-amyloid plaque relation. This fact is especially
relevant and deserves a deeper analysis, even more if we
take into account that extracellular histones induce in-
flammation and other toxic effects [51, 52]. It is also
relevant the result that suggests that fibronectin is re-
duced in AD extracts vs non-AD as major changes in
the molecular composition of the vascular basement
membranes (BM) are observed in acute and chronic
neuropathological settings [53]. Other proteins of the
extracellular matrix (ECM) intimately related with the
BM such as fibrinogen or laminin A5 are more abundant
in non-AD extracts while no differences were found on
tubulins or vimentin between non-AD and AD samples.
Therefore, the dissimilar distribution of these structural
components of the BM and the ECM between AD and
non-AD extracts reflects alteration of the BM that oc-
curs in AD [54].
It also shows that the alpha-3 subunit of type VI colla-
gen decreases in patients with AD. Collagen VI is an
extracellular matrix protein which, according to previous
studies [55], protects neurons from the toxicity of Aβ
peptides. Consequently, brains with collagen VI defi-
ciency can be expected to show greater vulnerability to
apoptosis, due to alterations in oxidative stress triggered
by Aβ deposits [56]. This protein could be a promising
focus for future treatments.
On the other hand, one of the most interesting pro-
teins observed exclusively in both samples of Aβ-
enriched extracts is the E3 ubiquitin-protein ligase
RNF213 [57]. RNA expression of the gene encoding this
protein was found in genomic microarrays from AD
patients [57]. Recent studies suggest that RNF213
plays an important role in cerebral blood flow main-
tenance under ischemic conditions by affecting angio-
genesis [58], processes whose alteration usually
precede development of amyloid plaques in AD pa-
tients and AD animal models [59]. Immunoreactivity
is mostly observed in the nucleus (increased in those
located inside the plaque), although, in the olfactory
cortex, the protein is also found within the plaque.
The distribution of RNF213 immunostaining reveals a
potential direct Aβ plaque biomarker. Contrary to
RNF213, CNTN1 was highly expressed in non-AD, as
opposed to AD, samples. The contactin family has
been known to interact with the extracellular domain
of amyloid precursor protein (APP). For instance,
contactin-2 regulates APP cleavage by secretases, a
process important for neurotoxic Aβ liberation and
production of the APP intracellular domain [60].
Also, it is implied in synaptic plasticity [61].
Table 2 Proteins found exclusively in AD extracts and proteins found exclusively in non-AD extracts (Continued)
Symbol Entrez gene name ID PSM
CNTN1 Contactin 1 Q12860 2
CWC25 CWC25 spliceosome associated protein homolog Q9NXE8 2
DIO3 Iodothyronine deiodinase 3 P55073 2
GDI1 GDP dissociation inhibitor 1 P31150 2
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Fig. 4 Double immunofluorescence against Aβ1–42, and GFAP (A), Aβ1–42 and ANXA5 (B) and Aβ1–42 and COL6A (C). Confocal images of
amygdala sections of human AD samples and non-AD samples, used to study the distribution of GFAP (green, A), ANXA5 (green, B), or COL6A
(green, C). Immunostaining against Aβ1–42 (red, a–b) was also included to identify the Aβ plaques. Nuclei are labeled in blue with DAPI.
Calibration bars 50 μm
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It is interesting that a number of specific calcium
binding (ANXA2, ANXA5, and FN1; [62–64]) or
calcium-sensitive (COL6A3 [65]) proteins are differen-
tially enriched in proteomics of both AD and non-AD
extracts. This fact may be related to the importance
that calcium plays in the progression of AD ([66])
where calcium increases are associated with increased
production of Aβ and also with reductions in macro-
autophagy—a clearance pathway for intracellular ag-
gregates—[67].
Conclusions
In conclusion, the obtained enriched Aβ fractions of hu-
man AD brains retain their ability to be internalized in
vitro by cultured cells, but also the intracellular detec-
tion in vivo of the labeled extracts was marked after 4
months post-inoculation. Therefore, the enriched Aβ ex-
tract allows for easy traceability by immunofluorescence
as the increased concentration of Aβ plaques amplifies
the cell exposure to Aβ. We have deeply characterized
the components of Aβ-enriched fractions identifying
Fig. 5 Triple immunofluorescence against Aβ1–42, RNF213, and CNTN1. Confocal images showing a triple-immunofluorescence against Aβ1–42 (a,
b), RNF213 (c, d), and CNTN1 (e, f) in coronal sections of non-AD (a, c, e, and g) and AD human brain (b, d, f, and h). Calibration bar a–h 50 μm.
Yellow arrowheads indicate the highly RNF213 immunofluorescence identified nuclei
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several proteins with dissimilar distribution between AD
and non-AD extracts and investigating the distribution
of the most representative findings in amygdala and
olfactory cortex. These unique characteristics in terms
of Aβ enrichment and extract characterization made
these extracts the finest tool to further investigate
seeding and transmissibility of the proposed prion-like
hypothesis of AD.
Additional files
Additional file 1: Table S1. Data of patients used in the present study.
AD, Alzheimer disease; non-AD, non-Alzheimer disease; M, Male; F, Fe-
male; y, years; P, Proteomic study; E, ELISA; D, dot blot; I, immunofluores-
cence. *Human brain tissue used for the optimization of the enrichment
protocol. Table S2. Antibodies used in the present study. (PPTX 47 kb)
Additional file 2: Figure S1. Schemes showing the medial view of the
brain and the corresponding levels: A) Coronal sections of olfactory (B)
and amygdaloid (C) areas analyzed [Bregma − 5.8 and − 6.7 mm
respectively, according to [68]]. The corresponding tissue blocks (D, E)
and Nissl-stained, mosaic-reconstructed sections (F, G) are also illustrated.
Calibration bars 1 cm. A: amygdala; aic: anterior limb of internal capsule;
AONc: anterior olfactory nucleus, cortical part; C: claustrum; cc: corpus cal-
losum; Cd: caudate nucleus; HiH: hippocampal head; ic: internal capsule;
LV: lateral ventricle; OlfA: olfactory area; Pir: piriform cortex; PHG: parahip-
pocampal gyrus; Pu: putamen; SG: straight gyrus; TLV: temporal horn of
lateral ventricle; un: uncus; Ent: Entorhinal cortex; PRC: perirhinal cortex.
Figure S2. Overview of the protocol for the enrichment of Aβ plaques
(A). Dot blot of the steps of Aβ plaque enrichment using Aβ1–42 antibody
(B–C) and tau antibody (D). Coomassie blue of the steps of Aβ enrich-
ment. AD, Alzheimer disease; Non-AD, non-Alzheimer disease; DP, diffuse
plaques; LB, lysis buffer; T, total extract; S, supernatant; P, pellet. Numbers
indicate steps in the procedure. Figure S3. Gene ontology overrepresen-
tation study. “p value” is the enrichment p value computed according to
the mHG or HG model. “FDR q value” is the correction of the above p
value for multiple testing using the Benjamini and Hochberg (1995)
method. Figure S4. Double immunofluorescence against Aβ1–42, and
ANXA5 (A), and triple immunofluorescence against Aβ1–42, RNF213 and
CNTN1 (B). Confocal images of human olfactory cortex sections of human
AD samples and non-AD samples to study the distribution of ANXA5
(green, A), RNF213 (green, B), or CNTN1 (purple, B). Immunostaining
against Aβ1–42 (red, A and B) was also included to identify Aβ plaques.
Nuclei are labeled in blue with DAPI. The arrow indicates nuclei located
inside the plaque. Calibration bars 50 μm. (PPTX 11881 kb)
Additional file 3: Video S1 (MP4 2166 kb)
Additional file 4: Table S3. Proteins identified by reverse-phase liquid
chromatography coupled to tandem mass spectrometry (RP-LC-MS/MS)
in AD1, AD2, non-AD1, and non-AD2 extracts. PSM, peptide-spectrum
matches. Coverage: % of the protein identified. #peptides, number of the
identified peptides corresponding to the identified protein. (XLSX 60 kb)
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